JP2022190158A - Composition for external use - Google Patents
Composition for external use Download PDFInfo
- Publication number
- JP2022190158A JP2022190158A JP2022178186A JP2022178186A JP2022190158A JP 2022190158 A JP2022190158 A JP 2022190158A JP 2022178186 A JP2022178186 A JP 2022178186A JP 2022178186 A JP2022178186 A JP 2022178186A JP 2022190158 A JP2022190158 A JP 2022190158A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- minoxidil
- composition
- external use
- alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title abstract description 64
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 48
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 abstract description 42
- 229960003632 minoxidil Drugs 0.000 abstract description 42
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 abstract description 34
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 abstract description 32
- 150000003839 salts Chemical class 0.000 abstract description 29
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 abstract description 17
- 229960003720 enoxolone Drugs 0.000 abstract description 17
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 abstract description 16
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 abstract description 16
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 abstract description 16
- 229940101267 panthenol Drugs 0.000 abstract description 16
- 235000020957 pantothenol Nutrition 0.000 abstract description 16
- 239000011619 pantothenol Substances 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 16
- 229930007845 β-thujaplicin Natural products 0.000 abstract description 16
- 239000004480 active ingredient Substances 0.000 abstract description 15
- 229960000520 diphenhydramine Drugs 0.000 abstract description 15
- 239000002253 acid Substances 0.000 abstract description 11
- 150000005846 sugar alcohols Polymers 0.000 abstract description 10
- 238000002156 mixing Methods 0.000 abstract description 7
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 2
- 238000002845 discoloration Methods 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 238000004040 coloring Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 230000000699 topical effect Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- -1 arachyl alcohol Chemical compound 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N heptadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- CAYHVMBQBLYQMT-UHFFFAOYSA-N 2-decyltetradecan-1-ol Chemical compound CCCCCCCCCCCCC(CO)CCCCCCCCCC CAYHVMBQBLYQMT-UHFFFAOYSA-N 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- FIPPFBHCBUDBRR-UHFFFAOYSA-N henicosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCO FIPPFBHCBUDBRR-UHFFFAOYSA-N 0.000 description 2
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- REIUXOLGHVXAEO-UHFFFAOYSA-N pentadecan-1-ol Chemical compound CCCCCCCCCCCCCCCO REIUXOLGHVXAEO-UHFFFAOYSA-N 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XFRVVPUIAFSTFO-UHFFFAOYSA-N 1-Tridecanol Chemical compound CCCCCCCCCCCCCO XFRVVPUIAFSTFO-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical group N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000408747 Lepomis gibbosus Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NWBJYWHLCVSVIJ-UHFFFAOYSA-N N-benzyladenine Chemical compound N=1C=NC=2NC=NC=2C=1NCC1=CC=CC=C1 NWBJYWHLCVSVIJ-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008609 bushi Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RZMKWKZIJJNSLQ-UHFFFAOYSA-M carpronium chloride Chemical compound [Cl-].COC(=O)CCC[N+](C)(C)C RZMKWKZIJJNSLQ-UHFFFAOYSA-M 0.000 description 1
- 229950003631 carpronium chloride Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229960003517 isothipendyl Drugs 0.000 description 1
- OQJBSDFFQWMKBQ-UHFFFAOYSA-N isothipendyl Chemical compound C1=CN=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 OQJBSDFFQWMKBQ-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- XGFDHKJUZCCPKQ-UHFFFAOYSA-N n-nonadecyl alcohol Natural products CCCCCCCCCCCCCCCCCCCO XGFDHKJUZCCPKQ-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- TXGSOSAONMOPDL-UHFFFAOYSA-N propan-2-yl 3,4,5-trihydroxybenzoate Chemical compound CC(C)OC(=O)C1=CC(O)=C(O)C(O)=C1 TXGSOSAONMOPDL-UHFFFAOYSA-N 0.000 description 1
- 235000020236 pumpkin seed Nutrition 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000010018 saw palmetto extract Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Abstract
Description
本発明は、ミノキシジルを有効成分とする外用組成物に関する。更に詳細には、グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分を配合したミノキシジル含有外用組成物の経時的な着色を抑制する技術に関する。 The present invention relates to an external composition containing minoxidil as an active ingredient. More specifically, a minoxidil-containing topical composition containing at least one active ingredient selected from the group consisting of glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts. The present invention relates to technology for suppressing coloration over time.
ミノキシジルは化学名を6-(1-ピペリジニル)-2,4-ピリミジンジアミン-3-オキサイドと称し、育毛剤としての適応が知られており(特許文献1)、優れた育毛・発毛効果を発揮する薬剤として多数の報告がある。
また、グリチルレチン酸は抗炎症作用があること(特許文献2)、パントテニールエチルエーテルは細胞賦活作用があること(特許文献3)、パンテノールは創傷治癒促進作用があること(特許文献4)、ヒノキチオールは抗菌作用があること(特許文献5)、ジフェンヒドラミンはかゆみ抑制作用があること(特許文献6)が報告されており、多くの育毛剤に用いられている。
Minoxidil, whose chemical name is 6-(1-piperidinyl)-2,4-pyrimidinediamine-3-oxide, is known to be applied as a hair restorer (Patent Document 1), and has excellent hair growth and growth effects. There are many reports as a drug that exerts
In addition, glycyrrhetinic acid has an anti-inflammatory effect (Patent Document 2), pantothenyl ethyl ether has a cell activating effect (Patent Document 3), panthenol has a wound healing promoting effect (Patent Document 4), Hinokitiol has been reported to have an antibacterial effect (Patent Document 5), and diphenhydramine has been reported to have an itch suppressing effect (Patent Document 6), and is used in many hair restorers.
本発明者らは、優れた育毛剤を開発するため、ミノキシジルと酸を含有する組成物に、特定の有効成分、すなわちグリチルレチン酸、パントテニールエチルエーテル、パンテノール、ヒノキチオール、又は塩酸ジフェンヒドラミンを配合したミノキシジル含有外用組成物を製造し、安定性を評価したところ、意外にも、特定の有効成分の配合によりミノキシジル単独製剤よりも着色が増悪することがわかった。本発明は、グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分を配合したミノキシジル含有外用組成物において、製剤の着色を抑制したミノキシジル含有外用組成物を提供することを課題とする。 In order to develop an excellent hair restorer, the present inventors formulated a composition containing minoxidil and an acid with specific active ingredients, namely glycyrrhetinic acid, pantothenyl ethyl ether, panthenol, hinokitiol, or diphenhydramine hydrochloride. A topical composition containing minoxidil was produced and its stability was evaluated. Surprisingly, it was found that the formulation of a specific active ingredient exacerbated the coloration compared to a minoxidil preparation alone. The present invention provides a minoxidil-containing topical composition containing at least one active ingredient selected from the group consisting of glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts, An object of the present invention is to provide a minoxidil-containing composition for external use in which the coloring of the preparation is suppressed.
今までに2w/w%以上のミノキシジルと、グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、又はジフェンヒドラミン及び/又はその塩との間に、製剤の着色増悪に影響を与えるような相互作用を生じるか否かについて、報告された例はない。 Between 2 w/w% or more of minoxidil and glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, or diphenhydramine and/or its salts, to affect the color exacerbation of the formulation There are no reported examples of whether such interactions occur.
本発明者らは、上記課題を解決すべく鋭意検討を重ねた結果、グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、又はジフェンヒドラミン及び/又はその塩を配合したミノキシジル含有外用組成物を製造する場合は、特定の多価アルコールを選択することにより、経時的な製剤の着色を抑制したミノキシジル含有外用組成物が製造できることを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventors have found a minoxidil-containing topical formulation containing glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, or diphenhydramine and/or its salts. When manufacturing the composition, the inventors have found that by selecting a specific polyhydric alcohol, it is possible to manufacture a minoxidil-containing topical composition that suppresses coloration of the preparation over time, and have completed the present invention.
すなわち本発明は、
(1)a)2w/w%以上のミノキシジル、
b)グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分、
c)プロピレングリコール、及び
d)酸を含有することを特徴とする外用組成物、
(2)ミノキシジルの濃度が5w/w%以上である(1)に記載の外用組成物、
(3)a)2w/w%以上のミノキシジル、
b)グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分、
c)プロピレングリコール、及び
d)酸を混合して混合物を調製する工程と、
前記混合物にe)水、f)低級アルコールを加えて全量調製する工程を含むことを特徴とする外用組成物の製造方法、
である。
That is, the present invention
(1) a) 2 w/w% or more of minoxidil,
b) at least one active ingredient selected from the group consisting of glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts;
A topical composition comprising c) propylene glycol and d) an acid,
(2) The topical composition according to (1), wherein the concentration of minoxidil is 5 w/w% or more;
(3) a) 2 w/w% or more of minoxidil,
b) at least one active ingredient selected from the group consisting of glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts;
mixing c) propylene glycol, and d) an acid to form a mixture;
A method for producing a composition for external use, comprising the step of adding e) water and f) a lower alcohol to the mixture to prepare the total amount,
is.
本発明により、グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分を配合した2w/w%以上のミノキシジル含有外用組成物において、製剤の経時的な着色を抑制したミノキシジル含有外用組成物を提供することが可能になった。 According to the present invention, 2 w/w% or more minoxidil containing at least one active ingredient selected from the group consisting of glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts. It has become possible to provide a minoxidil-containing composition for external use in which the coloration of the formulation over time is suppressed in the composition for external use.
本発明によれば、2w/w%以上のミノキシジル、グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分、プロピレングリコール、及び酸を含有する外用組成物は、ミノキシジル製剤の着色を抑制したものとなる。 According to the present invention, 2 w/w% or more of at least one active ingredient selected from the group consisting of minoxidil, glycyrrhetinic acid and/or salts thereof, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or salts thereof , propylene glycol, and acid suppresses the coloring of minoxidil preparations.
本発明の外用組成物において用いるミノキシジルは、通常医薬品に用いられる品質のものを適宜使用することができる。また、本発明によれば、ミノキシジルの含有量は2w/w%以上であり、さらに好ましくは3w/w%以上であり、さらにより好ましくは5w/w%以上である。5w/w%以上となると、より製剤の着色が進行するため、本発明ではこの範囲で実施する意義が大きい。 As for minoxidil used in the composition for external use of the present invention, minoxidil of a quality commonly used in pharmaceuticals can be appropriately used. Also, according to the present invention, the content of minoxidil is 2 w/w% or more, more preferably 3 w/w% or more, and even more preferably 5 w/w% or more. If the content is 5 w/w% or more, the coloration of the preparation progresses further, so it is significant to implement the content within this range in the present invention.
本発明の外用組成物において用いる多価アルコールは、本発明の効果である、製剤の経時的な着色を抑制する点からプロピレングリコールである。プロピレングリコールの配合量は、全組成物中好ましくは2~55w/w%であり、より好ましくは2~35w/w%であり、さらに好ましくは2~15w/w%である。本発明の外用組成物中には、本発明の効果を損なわない範囲でプロピレングリコール以外の多価アルコールを含んでもよいが、グリセリン、ポリエチレングリコール、ジプロピレングリコールは配合しない方が本発明の効果の点から好ましく、プロピレングリコールのみを配合することが本発明の効果の点から最も好ましい。 The polyhydric alcohol used in the composition for external use of the present invention is propylene glycol from the viewpoint of suppressing coloration of the formulation over time, which is the effect of the present invention. The blending amount of propylene glycol is preferably 2 to 55 w/w%, more preferably 2 to 35 w/w%, still more preferably 2 to 15 w/w% in the total composition. The composition for external use of the present invention may contain a polyhydric alcohol other than propylene glycol as long as it does not impair the effects of the present invention. From the point of view, it is most preferable from the point of view of the effect of the present invention to blend only propylene glycol.
ミノキシジルを基剤中に溶解させるためには酸を用いることが知られている。本発明の外用組成物において用いる酸としては、本発明の外用組成物の液性を7以下に調節する成分が好ましく、無機酸もしくは炭素数が6以下の有機酸が挙げられる。具体的にはリン酸、クエン酸、乳酸、塩酸、酢酸、硫酸、硝酸、酒石酸、マレイン酸、リンゴ酸、グルコン酸であり、好ましくはリン酸、クエン酸、乳酸、酒石酸である。これら酸を1種又は2種以上組み合わせてもよい。 It is known to use acids to dissolve minoxidil in bases. The acid used in the composition for external use of the present invention is preferably a component that adjusts the liquid property of the composition for external use to 7 or less, and includes inorganic acids and organic acids having 6 or less carbon atoms. Specifically, phosphoric acid, citric acid, lactic acid, hydrochloric acid, acetic acid, sulfuric acid, nitric acid, tartaric acid, maleic acid, malic acid and gluconic acid, preferably phosphoric acid, citric acid, lactic acid and tartaric acid. You may combine 1 type(s) or 2 or more types of these acids.
また、本発明の外用組成物は、主薬成分のミノキシジルの安定性、使用時の肌への刺激感、薬物の浸透性、使用感等の点から、そのpHを4.0~9.5の範囲に調整することが好ましく、5.0~7.0の範囲がさらに好ましい。さらに、pHの上限としては、好ましくは6.5未満であり、より好ましくは6.3以下、さらに好ましくは6.1以下である。 In addition, the composition for external use of the present invention has a pH of 4.0 to 9.5 from the viewpoints of the stability of minoxidil, which is the main ingredient, the feeling of irritation to the skin during use, the permeability of the drug, the feeling of use, etc. It is preferable to adjust it within a range, more preferably 5.0 to 7.0. Furthermore, the upper limit of the pH is preferably less than 6.5, more preferably 6.3 or less, still more preferably 6.1 or less.
本発明の外用組成物において用いるグリチルレチン酸及び/又はその塩の配合量は、本発明の着色を抑制するとの課題の点から外用組成物中0.01~1w/w%が好ましく、0.02~0.5w/w%がより好ましく、0.05~0.1w/w%が更に好ましく、また、ミノキシジル1質量部に対して0.02質量部以上が好ましい。パントテニールエチルエーテルの配合量は、本発明の着色を抑制するとの課題の点から外用組成物中0.1~5w/w%が好ましく、0.2~2w/w%がより好ましく、0.2~1w/w%が更に好ましく、また、ミノキシジル1質量部に対して0.2質量部以上が好ましい。パンテノールの配合量は、本発明の着色を抑制するとの課題の点から外用組成物中0.1~5w/w%が好ましく、0.2~2w/w%がより好ましく、0.2~1w/w%が更に好ましく、また、ミノキシジル1質量部に対して0.2質量部以上が好ましい。ヒノキチオールの配合量は、本発明の着色を抑制するとの課題の点から外用組成物中0.01~0.1w/w%が好ましく、0.01~0.05w/w%がより好ましく、0.02~0.05w/w%が更に好ましく、また、ミノキシジル1質量部に対して0.01質量部以上が好ましい。ジフェンヒドラミン及び/又はその塩の配合量は、本発明の着色を抑制するとの課題の点から外用組成物中0.01~1w/w%が好ましく、0.02~0.5w/w%がより好ましく、0.05~0.1w/w%が更に好ましく、また、ミノキシジル1質量部に対して0.02質量部以上が好ましい。 The amount of glycyrrhetinic acid and/or a salt thereof used in the composition for external use of the present invention is preferably 0.01 to 1 w/w%, preferably 0.02, in the composition for external use from the viewpoint of suppressing the coloring of the present invention. It is more preferably 0.5 w/w%, still more preferably 0.05 to 0.1 w/w%, and preferably 0.02 parts by mass or more per 1 part by mass of minoxidil. The content of pantothenyl ethyl ether is preferably 0.1 to 5 w/w%, more preferably 0.2 to 2 w/w%, more preferably 0.2 to 2 w/w% in the composition for external use from the viewpoint of suppressing coloring of the present invention. 2 to 1 w/w% is more preferable, and 0.2 parts by mass or more is preferable with respect to 1 part by mass of minoxidil. The amount of panthenol is preferably 0.1 to 5 w/w%, more preferably 0.2 to 2 w/w%, and more preferably 0.2 to 0.2 to 1 w/w% is more preferable, and 0.2 parts by mass or more is preferable with respect to 1 part by mass of minoxidil. The content of hinokitiol is preferably 0.01 to 0.1 w/w%, more preferably 0.01 to 0.05 w/w%, more preferably 0.01 to 0.05 w/w% in the topical composition from the viewpoint of suppressing coloring of the present invention. 0.02 to 0.05 w/w% is more preferable, and 0.01 part by mass or more is preferable with respect to 1 part by mass of minoxidil. The amount of diphenhydramine and/or a salt thereof is preferably 0.01 to 1 w/w%, more preferably 0.02 to 0.5 w/w%, in the topical composition from the viewpoint of suppressing the coloring of the present invention. Preferably, 0.05 to 0.1 w/w% is more preferable, and 0.02 parts by mass or more is preferable with respect to 1 part by mass of minoxidil.
本発明の外用組成物には、更に必要により高級アルコールを配合することができる。高級アルコールの例としては、炭素数が6~24のジアセトンアルコール、カプロイルアルコール、カプリリルアルコール、カプリルアルコール、ラウリルアルコール、トリデカノール、ミリスチルアルコール、ペンタデカノール、セチルアルコール、ヘキシルデカノール、イソセチルアルコール、セトステアリルアルコール、ヘプタデカノール、ステアリルアルコール、オレイルアルコール、イソステアリルアルコール、オクチルデカノール、ノナデカノール、アラキルアルコール、オクチルドデカノール、ヘンイコサノール、ベヘニルアルコール、デシルテトラデカノールがより好ましく、そのうち、ジアセトンアルコール、ラウリルアルコール、ミリスチルアルコール、セチルアルコール、ヘキシルデカノール、セトステアリルアルコール、ステアリルアルコール、イソステアリルアルコール、オレイルアルコール、アラキルアルコール、オクチルドデカノール、ベヘニルアルコール、デシルテトラデカノールがさらに好ましい。本発明の高級アルコールは、1種又は2種以上組み合わせて使用しても良い。高級アルコールの含有量は、外用組成物中0.05~10w/w%が好ましく、0.1~5w/w%がより好ましく、0.25~1.5w/w%が更に好ましい。 The composition for external use of the present invention may further contain a higher alcohol if necessary. Examples of higher alcohols include diacetone alcohol having 6 to 24 carbon atoms, caproyl alcohol, caprylyl alcohol, capryl alcohol, lauryl alcohol, tridecanol, myristyl alcohol, pentadecanol, cetyl alcohol, hexyldecanol, isocetyl alcohol, More preferred are cetostearyl alcohol, heptadecanol, stearyl alcohol, oleyl alcohol, isostearyl alcohol, octyldecanol, nonadecanol, arachyl alcohol, octyldodecanol, henicosanol, behenyl alcohol and decyltetradecanol, of which diacetone alcohol, More preferred are lauryl alcohol, myristyl alcohol, cetyl alcohol, hexyldecanol, cetostearyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, arachyl alcohol, octyldodecanol, behenyl alcohol and decyltetradecanol. You may use the higher alcohol of this invention 1 type or in combination of 2 or more types. The content of the higher alcohol is preferably 0.05 to 10 w/w%, more preferably 0.1 to 5 w/w%, even more preferably 0.25 to 1.5 w/w% in the composition for external use.
本発明の外用組成物には、更に必要により低級アルコールや水を配合することができる。低級アルコールとしては、炭素数1~5のものが好ましく、例えばエタノールやイソプロパノールなどが好ましく、これらを組み合わせて使用しても良い。低級アルコールの含有量は、全組成物中20w/w%以上が好ましく、より好ましくは30w/w%以上であり、より好ましくは35w/w%以上であり、更に好ましくは50w/w%以上である。水の配合量は、2~75w/w%が好ましく、より好ましくは5~50w/w%である。 The composition for external use of the present invention may further contain a lower alcohol or water, if necessary. As the lower alcohol, those having 1 to 5 carbon atoms are preferred, such as ethanol and isopropanol, and these may be used in combination. The content of the lower alcohol in the entire composition is preferably 20 w/w% or more, more preferably 30 w/w% or more, more preferably 35 w/w% or more, still more preferably 50 w/w% or more. be. The blending amount of water is preferably 2 to 75 w/w%, more preferably 5 to 50 w/w%.
本発明の外用組成物には、更に必要により高級脂肪酸を配合することができる。高級脂肪酸の例としては、炭素数10~22のものが好ましく、例えばイソステアリン酸、オレイン酸、ステアリン酸、カプリン酸、ラウリン酸、ミリスチン酸、パルミチン酸、パルミトレイン酸、リノール酸、リノレン酸、エライジン酸、アラキジン酸、アラキドン酸、ベヘン酸、エイコサペンタエン酸、ドコサヘキサエン酸等が挙げられ、これらを1種又は2種以上組み合わせてもよい。このうち、炭素数18のものが好ましく、特にイソステアリン酸又はオレイン酸が好ましい。高級脂肪酸の配合量は、全組成物中好ましくは0.1~10w/w%であり、より好ましくは1~6w/w%である。 The composition for external use of the present invention may further contain a higher fatty acid if necessary. Examples of higher fatty acids preferably have 10 to 22 carbon atoms, such as isostearic acid, oleic acid, stearic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, linoleic acid, linolenic acid, and elaidic acid. , arachidic acid, arachidonic acid, behenic acid, eicosapentaenoic acid, docosahexaenoic acid and the like, and these may be used singly or in combination of two or more. Among these, those having 18 carbon atoms are preferred, and isostearic acid or oleic acid is particularly preferred. The blending amount of the higher fatty acid is preferably 0.1 to 10 w/w%, more preferably 1 to 6 w/w%, in the total composition.
本発明の外用組成物には、更に必要により界面活性剤を配合することができる。しかしながら、界面活性剤の添加は、使用感やミノキシジルの皮膚吸収に影響を与える可能性があり、本発明の外用組成物では、界面活性剤を配合しなくてもミノキシジルの溶解性を確保できるため、実質的に界面活性剤を含まないものとすることが好ましい。 The composition for external use of the present invention may further contain a surfactant, if necessary. However, the addition of surfactants may affect the feeling of use and skin absorption of minoxidil, and in the composition for external use of the present invention, the solubility of minoxidil can be ensured without blending surfactants. , preferably substantially free of surfactants.
本発明の外用組成物においては、本発明の効果を損なわない範囲で、一般の外用剤に用いられる種々の活性成分や補助成分を配合することができる。例えば、賦形剤、育毛成分(6-ベンジルアミノプリン、アデノシン、ペンタデカン酸グリセリド、何首鳥等)、血管拡張剤(塩化カルプロニウム、ニコチン酸ベンジル、センブリ抽出液、オタネニンジンエキス、チクセツニンジンチンキ、トウガラシチンキ等)、抗ヒスタミン剤(塩酸イソチペンジル等)、抗炎症剤(グアイアズレン等)、角質溶解剤(尿素、サリチル酸等)、殺菌剤(グルコン酸クロルヘキシジン、イソプロピルメチルフェノール、第4級アンモニウム塩、ピロクトンオラミン等)、保湿剤(ヒアルロン酸又はその塩、コンドロイチン硫酸等)、各種動植物(イチイ、ボタンピ、カンゾウ、オトギリソウ、附子、ビワ、カワラヨモギ、コンフリー、アシタバ、サフラン、サンシシ、ローズマリー、セージ、モッコウ、セイモッコウ、ホップ、プラセンタ、ノコギリヤシ、パンプキンシード等)の抽出物、ビタミン類(酢酸レチノール、アスコルビン酸、硝酸チアミン、シアノコバラミン、ビオチン等)、抗酸化剤(ジブチルヒドロキシトルエン、ピロ亜硫酸ナトリウム、トコフェロール、エデト酸ナトリウム、アスコルビン酸、イソプロピルガレート等)、溶解補助剤(アジピン酸ジイソプロピル、ミリスチン酸イソプロピル、各種植物油、各種動物油、アルキルグリセリルエーテル、炭化水素類等)、代謝賦活剤、ゲル化剤(水溶性高分子等)、粘着剤、香料、清涼化剤(ハッカ油、カンフル等)、染料等の通常使用される成分を配合することができる。 The composition for external use of the present invention can contain various active ingredients and auxiliary ingredients used in general external preparations, as long as they do not impair the effects of the present invention. For example, excipients, hair-growth ingredients (6-benzylaminopurine, adenosine, pentadecanoic acid glyceride, Hekkei bird, etc.), vasodilators (carpronium chloride, benzyl nicotinate, assembly extract, panax ginseng extract, ginseng tincture, Capsicum tincture, etc.), antihistamines (isothipendyl hydrochloride, etc.), anti-inflammatory agents (guaiazulene, etc.), keratolytic agents (urea, salicylic acid, etc.), bactericides (chlorhexidine gluconate, isopropylmethylphenol, quaternary ammonium salts, piroctoneola) min, etc.), moisturizing agents (hyaluronic acid or its salts, chondroitin sulfate, etc.), various animals and plants (yew, botanpi, licorice, hypericum perforatum, Bushi, loquat, artemisia var. , Seymong, hops, placenta, saw palmetto, pumpkin seed, etc.), vitamins (retinol acetate, ascorbic acid, thiamine nitrate, cyanocobalamin, biotin, etc.), antioxidants (dibutyl hydroxytoluene, sodium pyrosulfite, tocopherol, edet) sodium acid, ascorbic acid, isopropyl gallate, etc.), solubilizers (diisopropyl adipate, isopropyl myristate, various vegetable oils, various animal oils, alkyl glyceryl ethers, hydrocarbons, etc.), metabolic activators, gelling agents (highly water-soluble molecules, etc.), adhesives, fragrances, refreshing agents (mint oil, camphor, etc.), dyes, and other commonly used ingredients can be blended.
本発明の外用組成物の剤形の例としては、液剤、ローション剤等が挙げられる。
本発明の外用組成物の調製は、常法に従い、上記各成分を含有することにより調製される。
Examples of dosage forms of the composition for external use of the present invention include liquids and lotions.
The composition for external use of the present invention is prepared according to a conventional method by containing each of the above components.
かくして得られる本発明の外用組成物は、頭髪用剤、睫毛用剤、眉毛用剤等の皮膚適用製剤等として使用することができる。 The composition for external use of the present invention thus obtained can be used as a preparation for skin application such as a preparation for hair, a preparation for eyelashes and a preparation for eyebrows.
本発明の外用組成物の製造方法としては、例えばa)2w/w%以上のミノキシジル、b)グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分、c)プロピレングリコール、及びd)酸を混合して混合物を調製し、その混合物にe)水及びf)低級アルコールを加えて全量調製する方法、a)2w/w%以上のミノキシジル、b)グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分、c)プロピレングリコール、d)酸、e)水を混合して混合物を調製し、その混合物にf)低級アルコールを加えて全量調製する方法などが挙げられる。 As a method for producing the composition for external use of the present invention, for example, a) 2 w/w% or more of minoxidil, b) glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts A method of preparing a mixture by mixing at least one active ingredient selected from the group consisting of c) propylene glycol and d) an acid, and adding e) water and f) a lower alcohol to the mixture to prepare the total amount, a b) at least one active ingredient selected from the group consisting of glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts, c) For example, propylene glycol, d) an acid, and e) water are mixed to prepare a mixture, and f) a lower alcohol is added to the mixture to prepare the total amount.
以下に、実施例、比較例及び参考例を記載し、本発明をさらに具体的に説明するが、本発明はこれら実施例等により何ら制約されるものではない。 Examples, Comparative Examples, and Reference Examples are described below to describe the present invention in more detail, but the present invention is not limited by these Examples and the like.
(実施例1~10、比較例1~17及び参考例1)
実施例1~10、比較例1~17及び参考例1の処方を表1~2に示す。表1~2に記載の各成分を混合、撹拌して溶解し、エタノールを加えて全量100gとして製剤を調製した。
(Examples 1 to 10, Comparative Examples 1 to 17 and Reference Example 1)
The formulations of Examples 1-10, Comparative Examples 1-17 and Reference Example 1 are shown in Tables 1-2. Each component shown in Tables 1 and 2 was mixed, stirred and dissolved, and ethanol was added to adjust the total amount to 100 g to prepare a formulation.
(試験方法1:熱安定性試験-1)
実施例1、比較例1~3及び参考例1の試験液を65℃(相対湿度成り行き)で3日間保管後、製剤を目視で観察し、色調を確認した。
(Test method 1: Thermal stability test-1)
After storing the test solutions of Example 1, Comparative Examples 1 to 3 and Reference Example 1 at 65° C. (relative humidity) for 3 days, the formulations were visually observed to confirm the color tone.
(結果)
表3から明らかなように、多価アルコールにプロピレングリコールを配合したミノキシジル含有製剤(実施例1)の着色は経時的に進行しなかった(無色)が、多価アルコールにプロピレングリコール以外を配合したミノキシジル含有製剤(比較例1~3)の着色は経時的に進行した(微黄色)。
(result)
As is clear from Table 3, the coloring of the minoxidil-containing preparation (Example 1) in which propylene glycol was blended with the polyhydric alcohol did not progress over time (colorless), but the polyhydric alcohol other than propylene glycol was blended. Minoxidil-containing formulations (Comparative Examples 1 to 3) developed coloration over time (pale yellow).
(試験方法2:熱安定性試験-2)
実施例2、及び比較例4~5の試験液を65℃(相対湿度成り行き)で5日間保管後、製剤を目視で観察し、色調を確認した。
(Test method 2: Thermal stability test-2)
After storing the test liquids of Example 2 and Comparative Examples 4 and 5 at 65° C. (relative humidity) for 5 days, the formulations were visually observed to confirm the color tone.
(結果)
表4から明らかなように、多価アルコールにプロピレングリコールを配合したミノキシジル含有製剤(実施例2)の着色は経時的に進行しなかった(無色)が、多価アルコールにプロピレングリコール以外を配合したミノキシジル含有製剤(比較例4~5)の着色は経時的に進行した(微黄色)。
(result)
As is clear from Table 4, the coloring of the minoxidil-containing preparation (Example 2) in which propylene glycol was blended with the polyhydric alcohol did not progress over time (colorless), but the polyhydric alcohol other than propylene glycol was blended. The coloration of minoxidil-containing preparations (Comparative Examples 4 and 5) progressed over time (pale yellow).
また,同じ微黄色でも、グリチルレチン酸の濃度が高い製剤の方が強い色調を示した。 In addition, even with the same faint yellow color, the preparation with a higher concentration of glycyrrhetinic acid showed a stronger color tone.
(試験方法3:熱安定性試験-3)
実施例3~10、比較例6~17及び参考例1の試験液を65℃(相対湿度成り行き)で5日間保管後、製剤を目視で観察し、色調を確認した。
(Test method 3: Thermal stability test-3)
After storing the test solutions of Examples 3 to 10, Comparative Examples 6 to 17 and Reference Example 1 at 65° C. (relative humidity trend) for 5 days, the formulations were visually observed to confirm the color tone.
(結果)
表5から明らかなように、多価アルコールにプロピレングリコールを配合したミノキシジル含有製剤(実施例3~10)の着色は経時的に進行しなかった(無色)が、多価アルコールにプロピレングリコール以外を配合したミノキシジル含有製剤(比較例6~17)の着色は経時的に進行した(微黄色又は黄色)。
(result)
As is clear from Table 5, the coloring of the minoxidil-containing formulations (Examples 3 to 10) in which propylene glycol was blended with the polyhydric alcohol did not progress over time (colorless), but when the polyhydric alcohol other than propylene glycol was used, the coloration did not progress over time. The coloration of the formulations containing minoxidil (Comparative Examples 6 to 17) progressed over time (pale yellow or yellow).
本発明により、グリチルレチン酸及び/又はその塩、パントテニールエチルエーテル、パンテノール、ヒノキチオール、ジフェンヒドラミン及び/又はその塩からなる群から選ばれる少なくとも1種の有効成分を配合したミノキシジル含有外用組成物において、製剤の経時的な着色を抑制したミノキシジル含有外用組成物を提供することが可能になった。 According to the present invention, a minoxidil-containing topical composition containing at least one active ingredient selected from the group consisting of glycyrrhetinic acid and/or its salts, pantothenyl ethyl ether, panthenol, hinokitiol, diphenhydramine and/or its salts, It has become possible to provide a minoxidil-containing composition for external use that suppresses coloration of the formulation over time.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023215705A JP2024026455A (en) | 2016-09-15 | 2023-12-21 | External composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016180100 | 2016-09-15 | ||
JP2016180100 | 2016-09-15 | ||
JP2017172074A JP7366515B2 (en) | 2016-09-15 | 2017-09-07 | External composition |
JP2021113393A JP2021165305A (en) | 2016-09-15 | 2021-07-08 | Composition for external use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021113393A Division JP2021165305A (en) | 2016-09-15 | 2021-07-08 | Composition for external use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023215705A Division JP2024026455A (en) | 2016-09-15 | 2023-12-21 | External composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022190158A true JP2022190158A (en) | 2022-12-22 |
Family
ID=61766011
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017172074A Active JP7366515B2 (en) | 2016-09-15 | 2017-09-07 | External composition |
JP2021113393A Pending JP2021165305A (en) | 2016-09-15 | 2021-07-08 | Composition for external use |
JP2022178186A Pending JP2022190158A (en) | 2016-09-15 | 2022-11-07 | Composition for external use |
JP2023215705A Pending JP2024026455A (en) | 2016-09-15 | 2023-12-21 | External composition |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017172074A Active JP7366515B2 (en) | 2016-09-15 | 2017-09-07 | External composition |
JP2021113393A Pending JP2021165305A (en) | 2016-09-15 | 2021-07-08 | Composition for external use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023215705A Pending JP2024026455A (en) | 2016-09-15 | 2023-12-21 | External composition |
Country Status (1)
Country | Link |
---|---|
JP (4) | JP7366515B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021014416A (en) * | 2019-07-10 | 2021-02-12 | ロート製薬株式会社 | External preparation |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988001502A1 (en) * | 1986-09-05 | 1988-03-10 | The Upjohn Company | Sebum-dissolving nonaqueous minoxidil formulation |
JP4467085B2 (en) * | 1996-01-05 | 2010-05-26 | 大正製薬株式会社 | Hinokitiol-containing composition |
JPH11263727A (en) * | 1997-12-03 | 1999-09-28 | Taisho Pharmaceut Co Ltd | Minoxidil formulated liquid preparation composition |
AUPP310798A0 (en) | 1998-04-22 | 1998-05-14 | Soltec Research Pty Ltd | Vehicle system for a composition comprising a piperidinopyrimidine derivative |
WO2001076540A1 (en) * | 2000-04-07 | 2001-10-18 | Taisho Pharmaceutical Co. Ltd. | Hair growth stimulant compositions |
JP2002326913A (en) | 2001-02-27 | 2002-11-15 | Taisho Pharmaceut Co Ltd | Hair growing composition |
JP2005314323A (en) | 2004-04-30 | 2005-11-10 | Sato Pharmaceutical Co Ltd | Hair growth formulation |
JP6244101B2 (en) | 2013-04-24 | 2017-12-06 | ロート製薬株式会社 | Minoxidil-containing external composition |
JP6261874B2 (en) * | 2013-04-24 | 2018-01-17 | ロート製薬株式会社 | Minoxidil-containing external composition |
WO2014184173A1 (en) | 2013-05-14 | 2014-11-20 | Montero Gida Sanayi Ve Ticaret A.S. | Hair care formulations |
JP6819275B2 (en) * | 2015-12-29 | 2021-01-27 | 大正製薬株式会社 | Topical solution |
-
2017
- 2017-09-07 JP JP2017172074A patent/JP7366515B2/en active Active
-
2021
- 2021-07-08 JP JP2021113393A patent/JP2021165305A/en active Pending
-
2022
- 2022-11-07 JP JP2022178186A patent/JP2022190158A/en active Pending
-
2023
- 2023-12-21 JP JP2023215705A patent/JP2024026455A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7366515B2 (en) | 2023-10-23 |
JP2024026455A (en) | 2024-02-28 |
JP2018048123A (en) | 2018-03-29 |
JP2021165305A (en) | 2021-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7099581B2 (en) | External composition | |
JP5699476B2 (en) | Hair growth | |
JP2022173381A (en) | Composition for external use | |
JP2024026455A (en) | External composition | |
JP2023171964A (en) | Composition for external use | |
JP6819275B2 (en) | Topical solution | |
JP7067581B2 (en) | Lotion | |
JP6825354B2 (en) | Topical composition | |
JP6528466B2 (en) | Composition for external use | |
WO2014168193A1 (en) | Composition for external use | |
JP7124435B2 (en) | external composition | |
JP7346010B2 (en) | External composition | |
JP7346838B2 (en) | External pharmaceutical composition | |
JP6821916B2 (en) | Topical composition | |
JP2021123587A (en) | Pharmaceutical composition for external use | |
JP2021167298A (en) | Pharmaceutical composition for external use | |
JP2021123586A (en) | Pharmaceutical composition for external use | |
JP2021123585A (en) | Pharmaceutical preparation for external use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221107 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231221 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240308 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240308 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240403 |